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Abstract    
Glucagon-like peptide 1 based therapies reduce hyperglycemia in type 2 diabetes. Diabetes 
cardiovascular co-morbidity remains prevalent though current treatments are effective at reducing 
hyperglycemia. Glucagon-like peptide 1 exerts specific actions on the cardiovascular system in both 
healthy individuals and patients with cardiovascular pathology, and glucagon-like peptide 1 therapies 
have improved the cardiovascular profile of diabetic patients. Glucagon-like peptide 1 exerts its action 
by binding to its receptor (glucagon-like peptide 1 receptor) at the cell surface. Mechanistically, it is 
not clear how GLP-1 therapies exert beneficial effects on the cardiovascular system. It is difficult to 
ascertain any conclusions on the ability of glucagon-like peptide 1 receptor agonism to reduce 
cardiovascular disease from animal/human studies due to varying experimental designs. This review 
highlights recent findings from long-term human glucagon-like peptide 1 therapy studies, and 
summarises postulated mechanisms as to how glucagon-like peptide 1 receptor agonism may alleviate 
cardiovascular disease. 
Keywords: Type 2 diabetes (T2D), cardiovascular (CV) disease (CVD), CV system (CVS), glucagon-like 
peptide 1 (GLP-1), GLP-1 receptor (GLP-1R), cardiovascular outcome trials (CVOTs), major adverse 
cardiac event (MACE). 
Type 2 diabetes (T2D) is a chronic complex multifactorial disease with an incompletely understood 
aetiology and pathogenesis 1,2. The majority of T2D patients are overweight (60-90% in western 
countries) implying that diets involving excessive nutrient consumption provoke disease pathogenesis 
3. However, this does not explain how individuals with a body mass index (BMI) of ≤25 develop T2D, 
and the majority of overweight individuals remain disease free 2,4. Interestingly, approximately 50% of 
T2D patients are not overweight in Japan5. It is also noteworthy that overweight patients have been 
reported to have a lower mortality rate due to cardiovascular (CV) disease (CVD) than normal-weight 
patients, termed ‘the obesity paradox’ 6. The obesity paradox implies that the diabetic phenotype 
promotes CVD independent of patient BMI. Despite current treatments being effective at reducing 
hyperglycemia, diabetes CV co-morbidity remains prevalent, and therefore novel therapies are 
desirable: approximately 75% of diabetic patients die from CVD 7. Evidence suggests that glucagon-
like peptide 1 (GLP-1) exerts specific actions on the CV system (CVS) in both healthy individuals and 
patients with CV pathology, and GLP-1 therapies have improved the CV profile of diabetic patients 8,9. 
The best characterised function of GLP-1 is its promotion of the incretin effect 9. The incretin effect is 
reduced in T2D - incretin hormones account for <20% of the insulin release after glucose ingestion in  
T2D patients compared to 70% in non-diabetic individuals 10. The current consensus is that GLP-1 levels 
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are normal in T2D but its action is reduced 11. GLP-1 has a very short half-life (~1.5min) due to its rapid 
proteolytic degradation in plasma by dipeptidyl peptidase IV (DPP-IV) enzymes 11. The DPP-IV resistant 
GLP-1 analogues are effective at reducing hyperglycemia in T2D patients, as they prolong the GLP-1 
response due to their extended half-lives 8. However, GLP-1 also has extrapancreatic functions (Fig. 1) 
9. Importantly, GLP-1 therapies induce weight loss, which is associated with reducing CVD in diabetic 
and non-diabetic subjects 8,9. GLP-1 based therapies also appear to exert other specific actions in 
diabetes 9.  
GLP-1 induces its effects by acting as an agonist to the GLP-1 receptor (GLP-1R). The effects induced 
by GLP-1 vary in different tissues as GLP-1R is coupled to a range of intracellular signalling pathways 
in different tissues, each of which promotes the desired physiological response elicited by receptor 
activation 12,13. GLP-1 also indirectly effects organs through the insulin secretion it promotes - 
approximately 28% of the postprandial insulin released into circulation is due to the action of this 
hormone 14,15. GLP-1R knock-out and knock-down studies in mice have demonstrated that the ability 
of GLP-1 to act as an incretin hormone is dependent on the presence of its receptor in islet beta-cells 
16,17. GLP-1R is a class B G-protein-coupled receptor (GPCR), consisting of a large hydrophilic N-terminal 
extracellular domain, seven hydrophobic transmembrane alpha-helices (TM1-7) joined by three 
hydrophilic extracellular loops (ECL1-3) and three intracellular loops (ICL1-3), and an intracellular C-
terminal domain. The GLP-1R C-terminal domain interacts with heterotrimeric G-proteins that consist 
of alpha, beta and gamma subunits that activate down-stream signalling pathways upon agonist (GLP-
1) binding (Fig. 2) 13,18-21.  
There are currently five licenced GLP-1 based therapies, one of which has two modes of delivery 
(exenatide as twice daily Byetta or once weekly Bydureon) 22, and semaglutide is being considered by 
regulatory authorities 23. These have differing levels of efficacy on glycaemic control and weight loss, 
perhaps due to differing GLP-1R activation of these drugs e.g. due to different penetration of the CNS 
24. Both animal and human studies generally suggest that GLP-1 therapies exert beneficial CV actions 
9.  
Chronic GLP-1R agonism in rodents was reported to reduce blood pressure (BP) and prevent 
hypertension 25-28. However, acute GLP-1 infusion in rodents increases heart rate (HR) and BP 9,29. 
Human short-term clinical trials have reported conflicting findings, as acute GLP-1 therapy has had no 
effect on BP and HR, or raised both 9. GLP-1 analogue and DPP-IV inhibition based therapies reduced 
plasma lipid levels in healthy and diabetic rodents, and the same therapies also had similar effects on 
T2D patients 9,30,31. However, one study found that exenatide treatment for 24 weeks had no effect on 
lipid profiles 32. Rodent in vitro studies have reported vasorelaxant actions of GLP-1, and different 
studies postulated different mechanisms as to how this was achieved 9. In vivo rodent studies have 
reported that GLP-1 induces vasodilation of certain blood vessels and promotes vasoconstriction of 
others, as well as improving endothelial function 9,33,34. Similarly, improved blood flow and endothelial 
function has been reported in diabetic individuals in response to acute GLP-1 therapies 9,35,36. 
Interestingly, exendin-4 treatment did not affect short-term triglyceride exposure induced endothelial 
dysfunction in rat femoral artery, which suggests that the reported in vivo beneficial actions of GLP-1 
therapies on the endothelium likely occurs via extracardiovascular GLP-1 signalling 37. Rodent and 
human studies have provided evidence that GLP-1 therapies have anti-atherosclerotic actions and 
angiogenic effects 9,38,39. GLP-1 therapies have been reported to reduce levels of pro-inflammatory 
molecules (associated with atherosclerotic development) in patients 9, and one study reported that 
anti-inflammatory benefits persisted for 12 weeks in obese T2D patients after a single exenatide 
injection 40. Finally, GLP-1 treatments during rodent and human in vitro/in vivo studies have been 
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reported to exert beneficial effects on the myocardium such as protection against diabetic 
cardiomyopathy 9.     
Long-term human studies have demonstrated that chronic DPP-IV inhibition did not significantly 
confer any CV benefits 41,42. In contrast, chronic GLP-1 based treatments demonstrated multiple CV 
benefits in diabetic subjects 9. Four cardiovascular outcome trials (CVOTs) have been reported for GLP-
1 analogues: ELIXA 43, LEADER 44, SUSTAIN 6 23 and EXSCEL 45 trials have tested lixisenatide, liraglutide, 
semaglutide and exenatide, respectively. ELIXA showed no advantage over placebo in terms of 
influencing primary outcome of a 4-point major adverse cardiac event (MACE) which included CV 
mortality, non-fatal myocardial infarction, non-fatal stroke and hospital admission for unstable angina 
43. The other CVOTs all used a 3-point MACE primary end-point (excluding unstable angina); superiority 
was demonstrated for liraglutide and semaglutide (albeit not a pre-specified analysis for semaglutide) 
but not for exenatide. All-cause mortality benefit was shown for liraglutide and exenatide but not for 
semaglutide, although the latter agent was tested in a smaller study. The ELIXA population all had a 
CV event within 180 days of the study start, and it is reasonable to assume that the stability of their 
coronary lesions would have made any drug effect difficult to determine. Conversely, the EXSCEL study 
included 27% of subjects at much lower CV risk which may have resulted in the marginal lack of 
statistical superiority. Examination of components of the primary end-point showed heterogeneity 
between the two trials that reported reduced CVD with GLP-1 analogues, with the LEADER superiority 
being driven by a significant reduction in CV mortality whilst SUSTAIN 6 superiority was largely due to 
a reduction in non-fatal stroke. In both of these studies, the mechanisms by which these drugs reduced 
CV outcomes is elusive. A moderator analysis of the LEADER study suggests that the reductions in 
HbA1c, weight and systolic blood pressure were insufficient to account for all of the benefit. Recently, 
an analysis of severe hypoglycaemia has also been shown not to influence the outcome. The slow 
separation of the event curves in the Kaplan-Meier plots from both LEADER and SUSTAIN 6 suggest an 
impact on the atherosclerotic process, which is in contrast to that seen with the sodium-glucose 
cotransporter 2 (SGLT2) inhibitors 46. 
Mechanistically, it is not clear how GLP-1 based therapies exert beneficial effects on the CVS, but 
studies have suggested several pathways (see Fig. 3). According to the postulated mechanisms, it 
appears that GLP-1 therapies mediate these effects directly and/or by promoting the incretin effect 2.  
By promoting the incretin effect, GLP-1 based therapies alleviate the potential of the diabetic 
phenotype to promote CVD by reducing hyperglycemia and hyperlipidemia, as well as by improving 
blood flow systemically due to increasing vascular nitric oxide production 8,9. These therapies also 
appear to promote the effects via direct mechanisms as well 9. Additionally, studies have found that 
GLP-1 therapies improve angiogenesis, reduce atherosclerosis progression, increase cardiac function, 
and improve prognosis of cardiac ischemia via the incretin effect and extrapancreatic GLP-1R activity 
8,9. Chronic GLP-1 therapies have also been reported to prevent hypertension, and evidence suggests 
this was achieved via CV GLP-1R activity 9. 
Currently, several studies are testing the chronic effects of other GLP-1 analogues 9. It is difficult to 
ascertain any conclusions about conflicting findings on the ability of GLP-1 based therapies to reduce 
CVD from animal and human studies: animal species and trial design differed between animal studies, 
and trial design and cohorts varied between human studies. The notion that the ‘inactive’ forms of 
GLP-1 may have direct effects on the CVS warrants investigation 47. The effect of allosteric GLP-1R 
agonists (discussed in 11) on the CVS is another area of future research. Better understanding of T2D 
aetiology/pathogenesis and how the disease phenotype promotes CVD, as well as further elucidation 
of GLP-1 activity/targets could enable better insight into the therapeutic potential of GLP-1R agonism 





Figure 1. Summary of the effects that GLP-1 has on various organs. Organs highlighted green do not 
express GLP-1R but GLP-1 has mediated direct insulin-like effects during experimental settings. This 
figure is adapted from: 8,12,14,48-50 
 
Figure 2. The canonical model of GLP-1R activation. Upon GLP-1 binding, the Gα subunit is activated 
by exchanging GDP for GTP, and then the G-protein subunits dissociate. Both the active Gα and Gβγ 
subunits activate down-stream effectors to propagate GPCR signalling. The intrinsic GTPase activity 
converts the Gα subunit bound GTP to GDP, and the G-protein subunits then re-associate ready for 
arrival of a new agonist. Adapted from: 11,13. 
 
Figure 3. Reported benefits of GLP-1R agonism on CVD. A summary of the reported benefits of GLP-1 
based therapies on reducing CVD burden in patients and in experimental settings, and the postulated 
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